Literature DB >> 9324193

Levodopa dependence and abuse in Parkinson's disease.

O Spigset1, C von Schéele.   

Abstract

Two patients with Parkinson's disease repeatedly increased their levodopa dosage on their own to 1500-2000 mg/day to reach and sustain a state of euphoria, regardless of the fact that dosages of 400-800 mg/day were sufficient to suppress their parkinsonian symptoms. Both were markedly unwilling to consent to recommendations of dosage reductions, and they readily accepted adverse effects such as hyperkinesias, anorexia, and hallucinations to achieve the positive mental effects. Thus, both patients fulfilled the diagnostic criteria for substance dependence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9324193

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  5 in total

Review 1.  Substance of abuse and movement disorders: complex interactions and comorbidities.

Authors:  Andres Deik; Rachel Saunders-Pullman; Marta San Luciano
Journal:  Curr Drug Abuse Rev       Date:  2012-09

2.  Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies.

Authors:  G Giovannoni; J D O'Sullivan; K Turner; A J Manson; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

Review 3.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  NLX-112, a highly selective 5-HT1A receptor biased agonist, does not exhibit misuse potential in male rats or macaques.

Authors:  R Depoortère; J Bergman; P M Beardsley; R I Desai; C A Paronis; D M Walentiny; M A Varney; A Newman-Tancredi
Journal:  Neuropharmacology       Date:  2022-03-09       Impact factor: 5.250

Review 5.  Emotional dysfunction in Parkinson's disease.

Authors:  Lee X Blonder; John T Slevin
Journal:  Behav Neurol       Date:  2011       Impact factor: 3.342

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.